Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, drawn from the whole corpus: 8 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether a menin inhibitor added to first-line therapy raises cure rates in NPM1-mutated AML.
MEN1 resistance mutations and how to sequence or combine inhibitors around them.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Dosing menin inhibitors safely with azoles and other QT-prolonging drugs.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Relapsed/refractory NPM1-mutated AML with no satisfactory alternative
CR 23%, ORR 33%, median OS 6.
A milestone in how this cancer is treated.
CR+CRh 22.
A milestone in how this cancer is treated.